Ultragenyx Pharmaceutical (NASDAQ:RARE) was upgraded by analysts at ValuEngine from a “hold” rating to a “buy” rating in a report released on Wednesday.
Several other research firms have also recently issued reports on RARE. Raymond James raised their price target on Ultragenyx Pharmaceutical from $53.00 to $57.00 and gave the company a “buy” rating in a report on Tuesday, November 6th. Canaccord Genuity decreased their price target on Ultragenyx Pharmaceutical from $90.00 to $75.00 and set a “buy” rating on the stock in a report on Wednesday, November 7th. Citigroup upgraded Ultragenyx Pharmaceutical from a “sell” rating to a “neutral” rating and raised their price target for the company from $46.00 to $54.00 in a report on Thursday, November 8th. They noted that the move was a valuation call. BidaskClub upgraded Ultragenyx Pharmaceutical from a “strong sell” rating to a “sell” rating in a report on Friday, November 23rd. Finally, Zacks Investment Research cut Ultragenyx Pharmaceutical from a “buy” rating to a “hold” rating in a report on Thursday, January 17th. Seven analysts have rated the stock with a hold rating and fourteen have given a buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $75.28.
Shares of RARE stock opened at $58.26 on Wednesday. The firm has a market cap of $2.87 billion, a PE ratio of -7.88 and a beta of 2.26. Ultragenyx Pharmaceutical has a 52 week low of $37.44 and a 52 week high of $90.98.
Ultragenyx Pharmaceutical (NASDAQ:RARE) last posted its quarterly earnings results on Tuesday, February 19th. The biopharmaceutical company reported ($1.73) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.74) by $0.01. The business had revenue of $16.26 million for the quarter, compared to analysts’ expectations of $13.30 million. Ultragenyx Pharmaceutical had a negative return on equity of 34.15% and a negative net margin of 383.75%. On average, research analysts expect that Ultragenyx Pharmaceutical will post -6.49 EPS for the current fiscal year.
In other Ultragenyx Pharmaceutical news, Director William Aliski sold 6,000 shares of the stock in a transaction dated Friday, December 7th. The stock was sold at an average price of $49.69, for a total value of $298,140.00. Following the transaction, the director now owns 72,610 shares of the company’s stock, valued at $3,607,990.90. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 8.40% of the company’s stock.
A number of large investors have recently added to or reduced their stakes in RARE. Dimensional Fund Advisors LP acquired a new position in Ultragenyx Pharmaceutical during the second quarter worth about $587,000. Bank of America Corp DE boosted its position in Ultragenyx Pharmaceutical by 62.2% during the second quarter. Bank of America Corp DE now owns 65,791 shares of the biopharmaceutical company’s stock worth $5,058,000 after acquiring an additional 25,219 shares during the last quarter. Advisors Asset Management Inc. acquired a new position in Ultragenyx Pharmaceutical during the second quarter worth about $181,000. Bank of New York Mellon Corp boosted its position in Ultragenyx Pharmaceutical by 1.9% during the second quarter. Bank of New York Mellon Corp now owns 207,662 shares of the biopharmaceutical company’s stock worth $15,963,000 after acquiring an additional 3,903 shares during the last quarter. Finally, First Trust Advisors LP boosted its position in Ultragenyx Pharmaceutical by 29.3% during the third quarter. First Trust Advisors LP now owns 1,263,466 shares of the biopharmaceutical company’s stock worth $96,453,000 after acquiring an additional 285,961 shares during the last quarter. 98.35% of the stock is currently owned by hedge funds and other institutional investors.
About Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of various products for the treatment of rare and ultra-rare genetic diseases in the United States. Its biologics product candidate includes Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII.
Recommended Story: Net Asset Value
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.